[Use of a minor fibrinolytic drug (mesoglycan) in phlebitis].
33 subjects (28 women and 5 men), aged 22-72 and suffering from various types and degrees of venous pathology (varicose syndromes, post-phlebitic syndromes, recent thrombophlebitis) were subjected to clinical study. All patients were treated with Mesoglycan, a fibrinolysis stimulating drug, in oral doses of 2 12 mg capsules 3 times a day for 30 days. The study was intended to show the effectiveness of such treatment, and consisted of a clinical and instrumental assessment of the subjective and objective symptoms associated with venous conditions. The results obtained were analysed statistically and confirmed the therapeutic effectiveness of Mesoglycan for this type of pathology, particularly for thrombophlebitis where treatment produced early and lasting results. In conclusion, both the experimental findings and the clinical results obtained, confirm the view that Mesoglycan is a drug of choice for the prevention and treatment of venous pathologies.
D000328:Adult; D000368:Aged; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000188:drug therapy; D011537:Pruritus / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy*; D014648:Varicose Veins / Q000188:drug therapy*
D006025:Glycosaminoglycans; C040617:mesoglycan
Sull'utilizzo di un farmaco fibrinolitico minore (Mesoglicano) nelle flebopatie.